Japanese 
English 
PRISM BioLab’s proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm. In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup,...
アーカイブ: ニュース
Informa Pharma Intelligence Award 2022 Biotech company of the year受賞
We are pleased to announce that we have won the Biotech company of the year in the Private category of the Informa Pharma Intelligence Award 2022, the Japanese version of the Scrip Awards, which have been held in the UK for 17 years. Read More | Event Report
PRISM BioLab、製薬大手のRoche社と Genentech社に対し独自開発のペプチド模倣技術を用いた低分子ライブラリーを提供
TOKYO, Japan, 5th Jan. 2022: — PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multitarget research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Read Full Press Release
エーザイとPRISM BioLab共同創製のCBP/β-catenin阻害剤E7386について、臨床におけるPOC（Proof of Concept：創薬概念の検証）を達成
エーザイ株式会社と株式会社PRISM BioLabは、このたび、両社が共同で創製した中分子化合物であるCREB-binding protein （CBP）/β-catenin阻害剤E7386について、臨床におけるPOC（Proof of Concept：創薬概念の検証）を達成したことをお知らせします。
株式会社PRISM BioLab、エーザイ株式会社より資金調達
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised ¥100 million in Series C funding through a third-party allotment to Eisai Co. Ltd. on October 14. PRISM has completed the series C financing of 1.4 billion yen in total and aims to achieve...
当社のペプチド模倣化合物に関する論文がACS Omegaに掲載されました
本稿では、ペプチド模倣化合物と実際のペプチドの構造との類似度を評価する手法を開発し、当社の化合物が優位性を示すことが述べられています。
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Takashima, Hajime; Yoshimori, Atsushi; Honda, Eiji; Taguri, Tomonori; Ozawa, Jun; Kasai, Masaji; Shuto,
Satoshi; Takehara, Dai
株式会社PRISM BioLab、13億円のシリーズC資金調達を実施
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. Read Full Press Release
Generalized-ensemble method study: A helix-mimetic compound inhibits protein-protein interaction by long-range and short-range intermolecular interactions
Journal of Computational Chemistry, 42(14), 956-969 (2021)
Higo, Junichi; Takashima, Hajime; Fukunishi, Yoshifumi; Yoshimori, Atsushi
E7386, a selective inhibitor of the interaction between β-catenin and CBP, exerts antitumor activity in tumor models with activated canonical wnt signaling
Cancer Research, 81(4), 1052-1062 (2021)
Yamada, Kazuhiko; Hori, Yusaku; Inoue, Satoshi; Yamamoto, Yuji; Iso, Kentaro; Kamiyama, Hiroshi; Yamaguchi, Atsumi; Kimura, Takayuki; Uesugi, Mai; Ito, Junichi; Matsuki, Masahiro; Nakamoto, Kazutaka; Harada, Hitoshi; Yoneda, Naoki; Takemura, Atsushi; Kushida, Ikuo; Wakayama, Naomi; Kubara, Kenji; Kato, Yu; Semba, Taro; Yokoi, Akira; Matsukura, Masayuki; Odagami, Takenao; Iwata, Masao; Tsuruoka, Akihiko; Uenaka, Toshimitsu; Matsui, Junji; Matsushima, Tomohiro; Nomoto, Kenichi; Kouji, Hiroyuki; Owa, Takashi; Funahashi, Yasuhiro; Ozawa, Yoichi